...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Biocon Launches Haselmeier’s Insulin Pen in India

| Print |
Tuesday, 22 November 2011 10:15 (UTC + 1)

Haselmeier_Logo

Zurich, Switzerland, November 22, 2011 / B3C newswire / - Haselmeier has announced that Biocon, one of Asia’s premier biotechnology companies, has launched INSUPen® in India. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen®, for use with Biocon’s insulin and insulin analogues.
The first launch of the INSUPen® has taken place with Biocon’s Basalog® and Insugen® insulins.

The INSUPen® is a reusable insulin pen based on Haselmeier’s popular i-pen technology. It is designed to be easy to use for the patient and provide accurate and reliable dosing. The INSUPen® is available in 3 attractive colors and is currently custom designed for use with both Basalog® and Insugen®, thus maximizing patient convenience.

The INSUPen® provides diabetic patients an attractive pen with user-friendly features at an affordable cost. Haselmeier is proud to work with Biocon, a premier biotechnology company, on this important program to develop and supply INSUPen®and we look forward to a long and successful partnership,” said Volker Wirth, Director Business Development & Marketing at Haselmeier.

Rakesh Bamzai, President, Marketing at Biocon added: “I am confident that INSUPen® will be a delight for patients and a value enhancer for all stakeholders.”


About Haselmeier GmbH
Haselmeier is a leading designer and manufacturer of pen and auto-injection systems. The Company’s devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. For more information visit: www.Haselmeier.com

About Biocon Limited
Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).


Contact
Haselmeier GmbH
Nadia Di Secli
Dufourstr. 32
CH-8008 Zürich
Switzerland
Tel.: + 41 44 250 52 40
This e-mail address is being protected from spambots. You need JavaScript enabled to view it